-+ 0.00%
-+ 0.00%
-+ 0.00%

Scancell Reports 74% Progression-Free Survival at 16 Months in Phase 2 Melanoma Trial with iSCIB1+

Reuters·12/09/2025 07:00:26

Please log in to view news